As the global pharmaceutical industry braces for a wave of patent expirations that could erase up to $400 billion in revenue by 2033, a new breed of investors is stepping in to reshape the biotech funding landscape. Among them, Jeito Capital has emerged as a standout player, leveraging a focused, high-conviction investment model that is already delivering significant returns.
A Growing Force in European Biopharma
Founded by physician scientist Rafaèle Tordjman, Jeito Capital has rapidly scaled its presence in the European life sciences ecosystem. The Paris-based firm recently closed its second fund at €1 billion, marking a record for an independent European biopharma fund. This milestone builds on the success of its first fund, which raised $630 million in 2021.
Over the past five years, Jeito has tripled its assets under management to €1.6 billion, reflecting strong investor confidence in its differentiated strategy. At a time when large pharmaceutical companies are actively seeking innovative therapies to offset looming revenue losses, firms like Jeito are becoming critical partners in the drug development pipeline.
A High-Conviction Investment Strategy
Unlike traditional venture capital models that spread capital across a broad portfolio of early-stage startups, Jeito adopts a concentrated approach. The firm typically invests up to €150 million in each company, focusing on 15 to 20 clinical-stage biotech businesses.
This strategy directly addresses a persistent gap in European biotech funding. Many founders struggle to secure the substantial, long-term capital required to advance drugs through late-stage clinical trials, particularly Phases 2 and 3. As a result, most European biotech firms have historically turned to international markets, with nearly all recent public listings occurring outside the European Union.
By committing larger sums to fewer companies, Jeito enables these firms to progress further in development without constant fundraising pressures.
Beyond Capital: Operational Expertise
Jeito’s value proposition extends well beyond financial backing. The firm provides hands-on support across critical areas such as drug development, regulatory strategy, manufacturing, and market access. These capabilities are often out of reach for smaller biotech companies but are essential for transforming promising clinical data into commercially viable therapies.
This integrated approach is particularly important in late-stage development, where operational execution can determine whether a drug successfully reaches patients and achieves market adoption.
Strong Exit Momentum in 2024
Jeito’s model gained significant validation in 2024 through two major acquisitions. Merck & Co. acquired EyeBio, a Jeito portfolio company, for up to $3 billion. In the same month, Biogen purchased HI-Bio for up to $1.8 billion.
These back-to-back deals generated nearly $5 billion in value, highlighting the firm’s ability to identify and scale high-potential assets that attract global pharmaceutical buyers.
Differentiation in a Competitive Landscape
Jeito distinguishes itself from other European investors such as Sofinnova Partners, Forbion, and Novo Holdings through its exclusive focus on mid- to late-stage clinical investments.
Additionally, the firm maintains a Europe-first strategy and is led by a multidisciplinary team of scientists, regulatory specialists, and commercial experts rather than generalist investors. This domain expertise allows for deeper involvement in portfolio companies and more informed decision-making.
Looking Ahead: Sustaining the Momentum
While the success of recent exits underscores Jeito’s potential, questions remain about whether this performance can be consistently replicated. The firm’s current portfolio will be closely watched for further validation.
One notable investment is Alveus Therapeutics, which raised $197 million in a Series A round in February 2026 with Jeito as the lead investor. The company is developing next-generation treatments for obesity, one of several therapeutic areas Jeito is targeting, alongside oncology, neurology, autoimmune diseases, reproductive health, and cardiometabolic conditions.
As pharmaceutical giants continue to seek innovation to offset declining revenues, Jeito Capital’s focused, expertise-driven model positions it as a key enabler of the next wave of breakthrough therapies and a compelling opportunity for investors.
